Click Here for 5% Off Your First Aladdin Purchase!

Tirbanibulin - 98%, high purity , Tyrosine-protein kinase SRC inhibitor, CAS No.897016-82-9, Tyrosine-protein kinase SRC inhibitor

  • Moligand™
  • ≥98%
Item Number
K126255
Grouped product items
SKUSizeAvailabilityPrice Qty
K126255-1mg
1mg
In stock
$17.90
K126255-5mg
5mg
In stock
$70.90
K126255-10mg
10mg
In stock
$86.90
K126255-25mg
25mg
In stock
$195.90
K126255-50mg
50mg
In stock
$336.90
K126255-100mg
100mg
In stock
$576.90
K126255-250mg
250mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$1,298.90

Basic Description

SynonymsKX2-391|897016-82-9|Tirbanibulin|KX-01|N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide|Klisyri|KX-2-391|KX01|KX-2391|KX2391|UNII-4V9848RS5G|Tirbanibulin [USAN]|4V9848RS5G|KX 01|CHEMBL571546|2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)et
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological Mechanisms

KX2-391 is an orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, Src kinase inhibitor KX2-391 specifically binds to the pe

Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionTyrosine-protein kinase SRC inhibitor

Product Properties

ALogP2.9

Names and Identifiers

IUPAC Name N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide
INCHI InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)
InChi Key HUNGUWOZPQBXGX-UHFFFAOYSA-N
Canonical SMILES C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
Isomeric SMILES C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
PubChem CID 23635314
Molecular Weight 431.53

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

7 results found

Lot NumberCertificate TypeDateItem
A2208043Certificate of AnalysisOct 10, 2023 K126255
A2208059Certificate of AnalysisOct 10, 2023 K126255
A2208067Certificate of AnalysisOct 10, 2023 K126255
A2208069Certificate of AnalysisOct 10, 2023 K126255
A2208070Certificate of AnalysisOct 10, 2023 K126255
A2208109Certificate of AnalysisOct 10, 2023 K126255
A2208110Certificate of AnalysisOct 10, 2023 K126255

Chemical and Physical Properties

SolubilityDMSO 86 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

Related Documents

References

1. Lau GM, Lau GM, Yu GL, Gelman IH, Gutowski A, Hangauer D, Fang JW.  (2009)  Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro..  Dig Dis Sci,  54  (7): (1465-74).  [PMID:18979199]
2. Pevet I, Brulé C, Tizot A, Gohier A, Cruzalegui F, Boutin JA, Goldstein S.  (2011)  Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors..  Bioorg Med Chem,  19  (8): (2517-28).  [PMID:21459579]
3. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG.  (2012)  KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer..  Breast Cancer Res Treat,  132  (2): (391-409).  [PMID:21509526]
4. Fallah-Tafti A, Foroumadi A, Tiwari R, Shirazi AN, Hangauer DG, Bu Y, Akbarzadeh T, Parang K, Shafiee A.  (2011)  Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities..  Eur J Med Chem,  46  (10): (4853-8).  [PMID:21852023]
5. Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA.  (2013)  A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies..  Invest New Drugs,  31  (4): (967-73).  [PMID:23361621]
6. Markham A, Duggan S.  (2021)  Tirbanibulin: First Approval..  Drugs,  129  (3): (589-97).  [PMID:33713299]
7. Smolinski MP, Bu Y, Clements J, Gelman IH, Hegab T, Cutler DL, Fang JWS, Fetterly G, Kwan R, Barnett A et al..  (2018)  Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)..  J Med Chem,  61  (11): (4704-4719).  [PMID:29617135]

Solution Calculators